Immunome, Inc.
IMNMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United. With a market capitalization of $3.04B, it sits in mid-cap territory. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Market Cap
$3.04B
Beta
2.13
P/E (TTM)
—
P/E (Fwd)
-10.79
EPS (TTM)
$-2.53
EPS (Fwd)
$-2.48
ROE
-64.0%
ROA
-37.8%
Cash
$520.0M
Total Debt
$4.7M
Free CF
-$143.7M
52W Change
190.6%
Annual Financials
Cash vs Debt
Where IMNM stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, IMNM finished 19.25% above its 150-day moving average ($22.70) and 22.10% above its 200-day moving average ($22.17). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMNM overbought or oversold?
At the September 2, 2026 close, IMNM's RSI(14) was 46.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $520.0M in cash comfortably exceeding the $4.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$143.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -64.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, IMNM tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IMNM.